Related Experiment Video
Updated: May 30, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
Pitchai Balakumar1, Nanjaian Mahadevan
1Cardiovascular Pharmacology Division, Department of Pharmacology, Institute of Pharmacy, Rajendra Institute of Technology and Sciences, Sirsa, India. pbala2006@gmail.com
British Journal of Pharmacology
|July 28, 2011
Summary
Statins manage high cholesterol by inhibiting HMG-CoA reductase. Emerging research reveals statins also activate PPARs, contributing to their cardiovascular protective effects beyond cholesterol reduction.
Area of Science:
- Cardiovascular Pharmacology
- Molecular Biology
Background:
- Statins are primary medications for managing hypercholesterolemia and preventing cardiovascular disease.
- Their efficacy is attributed to inhibiting HMG-CoA reductase, thereby reducing cholesterol synthesis.
- Statins offer cardioprotective benefits through pleiotropic effects like anti-inflammatory and endothelial function improvements.
Purpose of the Study:
- To review the mechanisms of statin action, focusing on their cholesterol-lowering and pleiotropic effects.
- To explore the emerging role of statins in modulating nuclear transcription factors, particularly PPARs.
- To elucidate the interplay between statins and PPARs in cardiovascular protection.
Main Methods:
- Literature review of studies on statin pharmacology and cardiovascular effects.
- Analysis of research investigating statin interactions with nuclear transcription factors.
- Synthesis of evidence regarding the dual mechanisms of statin action.
Main Results:
- Statins effectively lower cholesterol by inhibiting HMG-CoA reductase.
- Statins exhibit pleiotropic effects, including anti-inflammatory and antioxidant properties.
- Evidence suggests statins activate PPARs, which may mediate their cardiovascular protective actions.
Conclusions:
- Statins possess a dual mechanism of action: cholesterol reduction and PPAR activation.
- PPAR activation by statins likely contributes significantly to their cardioprotective pleiotropic effects.
- Further research into the statin-PPAR axis may reveal novel therapeutic strategies for cardiovascular complications.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...